The lipopolysaccharide of Bordetella bronchiseptica acts as a protective shield against antimicrobial peptides.
Resistance profiles of the two Bordetella species B. bronchiseptica and B. pertussis against various antimicrobial peptides were determined in liquid survival and agar diffusion assays. B. bronchiseptica exhibited significantly higher resistance against all tested peptides than B. pertussis. The most powerful agents acting on B. bronchiseptica were, in the order of their killing efficiencies, cecropin P > cecropin B > magainin-II-amide > protamine > melittin. Interestingly, for B. bronchiseptica, the resistance level was significantly affected by phase variation, as a bvgS deletion derivative showed an increased sensitivity to these peptides. Tn5-induced protamine-sensitive B. bronchiseptica mutants, which were found to be very susceptible to most of the cationic peptides, were isolated. In two of these mutants, the genetic loci inactivated by transposon insertion were identified as containing genes highly homologous to the wlbA and wlbL genes of B. pertussis that are involved in the biosynthesis of lipopolysaccharide (LPS). In agreement with this finding, the two peptide-sensitive mutants revealed structural changes in the LPS, resulting in the loss of the O-specific side chains and the prevalence of the LPS core structure. This demonstrates that LPS plays a major role in the resistance of B. bronchiseptica against the action of antimicrobial peptides and suggests that B. pertussis is much more susceptible to these peptides due to the lack of the highly charged O-specific sugar side chains.
Banemann
A
A
Lehrstuhl für Mikrobiologie, Theodor-Boveri-Institut, Biozentrum der Universität Würzburg, D-97074 Würzburg, Germany.
Deppisch
H
H
Gross
R
R
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D023181:Antimicrobial Cationic Peptides; D016950:Bordetella bronchiseptica / Q000187:drug effects* / Q000235:genetics / Q000472:pathogenicity; D001886:Bordetella pertussis / Q000187:drug effects; D002412:Cations / Q000494:pharmacology; D003001:Cloning, Molecular; D004351:Drug Resistance; D005798:Genes, Bacterial; D019476:Insect Proteins / Q000494:pharmacology; D008070:Lipopolysaccharides / Q000096:biosynthesis; D054806:Magainins; D008555:Melitten / Q000494:pharmacology; D008826:Microbial Sensitivity Tests; D016254:Mutagenesis, Insertional; D010455:Peptides / Q000494:pharmacology*; D016133:Polymerase Chain Reaction; D011479:Protamines / Q000494:pharmacology; D013045:Species Specificity; D029867:Xenopus Proteins
D000900:Anti-Bacterial Agents; D023181:Antimicrobial Cationic Peptides; D002412:Cations; D019476:Insect Proteins; D008070:Lipopolysaccharides; D054806:Magainins; D010455:Peptides; D011479:Protamines; D029867:Xenopus Proteins; C053301:magainin 2 peptide, Xenopus; D008555:Melitten